Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers

Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32^nd Annual Meeting.<br /> &nbsp;